Thursday, August 13th, 2026 - Day 3 - EST/EDT (Eastern Daylight, GMT-4)
An exclusive forum for senior compliance, transparency and HCP engagement leaders to discuss shared challenges, emerging pressures, and the evolving role of the function across the industry.
- Segment 1: Leadership Perspectives & Industry Priorities – Discuss top-of-mind issues such as global reporting complexities, AI adoption, and evolving enforcement trends
- Segment 2: Executive Dialogue to Navigate Emerging Pressures – Explore strategies for balancing innovaton with compliance, managing risk during organizational change, and preparing for heightened scrutiny
- Segment 3: Collaborative Case Discussions – Work through real-world scenarios on aggregate spend audits, cross-border transfers, and system integration challenges
*This summit is an exclusive, senior-level benchmarking discussion. Attendees should have a minimum of 5 years’ experience in compliance and transparency and be currently employed at a bio/pharmaceutical or medical device manufacturer. Informa Connect reserves the right to qualify participants for this Summit. To reserve your seat, please email nhu.tran@informa.com.
- Melissa Ince - Director, Global Transparency Reporting, Abbott Laboratories
Interactive, small-group sessions designed for practical discussions, idea-sharing and collaborative problem-solving. The solution circles are designed to help participants apply learning from the conference and address any outstanding gaps.
- Segment 1: Operational Challenges – Rotate through topic-focused circles on issues like:
- Managing speaker program documentation and FMV justification
- Streamlining aggregate spend data collection and validation
- Coordinating cross-functional workflows for HCP engagement approvals
- Segment 2: Risk Scenarios – Work through realistic cases such as:
- Detecting red flags in HCP contracting or advisory board engagements
- Identifying gaps in Open Payments reporting before audits
- Responding to compliance breaches during global transfers of value
- Andrea Jenner - Transparency Reporting Manager, CSL Seqirus
- Panelists from key partner functions, including finance, IT, data governance, and commercial operations, share how they work with transparency and HCP engagement teams to resolve challenges and improve operational efficiency
- Learn where collaboration breaks down, how to avoid common pitfalls, and what practical steps teams can take to strengthen communication and alignment
- Leave with best practices for building durable partnerships that support compliance accuracy. Reduce risk, and improve business readiness
- Sara Merin - Senior Assistant General Counsel, US Office of Ethics & Compliance, Bayer
- Itzy Wallace - Global Senior Director, Head of Compliance & Risk, Mayne Pharma
- Hear directly from companies of varying sizes and maturity levels as they share firsthand experiences navigating recent CMS audits, including what surprised them, what worked well, and what they would approach differently next time
- Explore practical insights into documentation readiness, data quality expectations, business partner coordination, and how to prepare teams for requests, follow-ups, and timelines
- Gain actionable takeaways for strengthening internal controls, streamlining audit preparation, and building a more confident, resilient reporting function, regardless of company size or resources
- Jonathan Wozniak - Head of Global Transparency Reporting, Daiichi Sankyo, Inc.
- Brian Bohnenkamp - Partner, FDA & Life Sciences, King & Spalding
- Examine how new engagement formats, including HCP social media influencers, digital educators, and advisory boards are creating unfamiliar compliance and reporting considerations in the US market
- Review emerging signals from regulators, industry standards, and enforcement commentary around transparency, promotion, fair market evaluation, and appropriate use of compensation for HCPs engagement through digital channels
- Discuss practical guidance for valuing and documenting these engagements, including criteria for assessing influence, establishing fair market value, clarifying deliverables, and ensuring consistent oversight across non-traditional HCP activities
- Aisha Ghazi Babar - Chief Compliance Officer, Pierre Fabre
- A fast-paced, forward-looking conversation highlighting the biggest shifts, signals, and opportunities shaping the next era of transparency and HCP engagement
- Hear as industry experts reflect on key theme from the conference and what teams should be preparing for in the years ahead
- Explore where the industry is heading and how organizations can work together to build a more integrated, resilient, and forward-thinking programs
- Karen Lowney - Head of Ethics & Compliance, Sun Pharmaceutical Industries, Inc.
